$NOVN.SW #Switzerland #CHF #Stocks #MedicalResearch
A global healthcare company based in Switzerland
Target Price: CHF97.26
Novartis AG (NYSE: NVS) said it has finalized its previously disclosed agreement with the U.S. Attorney’s Office for the Southern District of New York, the New York State attorney general and relator Oswald Bilotta resolving a civil suit challenging speaker programs and other promotional events conducted from 2002 through 2011 by Novartis in the U.S.
The litigation pertains to Novartis allegedly spending millions of dollars on incentive programs to doctors who steered patients toward drugs from its cardiovascular division in exchange for illegal kickbacks.
As part of this settlement, Novartis said it will pay $678 million and has agreed to new corporate integrity obligations with the Office of Inspector General of the Department of Health & Human Services that will change how the company delivers peer-to-peer programs in the U.S. The company said it had fully provisioned for this settlement in July 2019.
Novartis AG is a holding company, which provides healthcare solutions.
The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals.
The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers.
Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents.
Alcon researches, develops, manufactures, distributes and sells eye care products.
Alcon is a provider of eye care with product offerings in eye care devices and vision care.
The Company’s range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.
Shayne Heffernan Trade Idea
“Our current price target of Novartis will come in around CHF97.26 giving the stock a price increase of +18.06%.”
Overall, the bias in prices is: Downwards.
The projected upper bound is: 86.04.
The projected lower bound is: 78.59.
The projected closing price is: 82.31.
A black body occurred (because prices closed lower than they opened).
During the past 10 bars, there have been 4 white candles and 6 black candles for a net of 2 black candles. During the past 50 bars, there have been 23 white candles and 27 black candles for a net of 4 black candles.
Momentum is a general term used to describe the speed at which prices move over a given time period. Generally, changes in momentum tend to lead to changes in prices. This expert shows the current values of four popular momentum indicators.
One method of interpreting the Stochastic Oscillator is looking for overbought areas (above 80) and oversold areas (below 20). The Stochastic Oscillator is 34.1521. This is not an overbought or oversold reading. The last signal was a buy 2 period(s) ago.
Relative Strength Index (RSI)
The RSI shows overbought (above 70) and oversold (below 30) areas. The current value of the RSI is 46.06. This is not a topping or bottoming area. A buy or sell signal is generated when the RSI moves out of an overbought/oversold area. The last signal was a buy 71 period(s) ago.
Commodity Channel Index (CCI)
The CCI shows overbought (above 100) and oversold (below -100) areas. The current value of the CCI is -83. This is not a topping or bottoming area. The last signal was a sell 7 period(s) ago.
The Moving Average Convergence/Divergence indicator (MACD) gives signals when it crosses its 9 period signal line. The last signal was a sell 4 period(s) ago.
Rex Takasugi – TD Profile
NOVARTIS N closed down -0.660 at 82.380. Volume was 71% below average (consolidating) and Bollinger Bands were 46% narrower than normal.
Open High Low Close Volume 82.930 83.000 82.150 82.380 2,548,821
Technical Outlook Short Term: Neutral Intermediate Term: Bullish Long Term: Bearish
Moving Averages: 10-period 50-period 200-period Close: 83.79 83.40 86.14 Volatility: 21 28 32 Volume: 4,309,311 6,443,077 7,031,608
Short-term traders should pay closer attention to buy/sell arrows while intermediate/long-term traders should place greater emphasis on the Bullish or Bearish trend reflected in the lower ribbon.
NOVARTIS N is currently 4.4% below its 200-period moving average and is in an upward trend. Volatility is relatively normal as compared to the average volatility over the last 10 periods.
Our volume indicators reflect volume flowing into and out of NOVN.S at a relatively equal pace (neutral). Our trend forecasting oscillators are currently bullish on NOVN.S and have had this outlook for the last 11 periods.
Latest posts by HEFFX Australia (see all)
- Hocquart History: A classic prep on a new path - August 7, 2020
- Hocquart Longines Preview: A battle of three parties - August 7, 2020
- Five head-to-heads we could see in 2020 - August 7, 2020